Cargando…
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977089/ https://www.ncbi.nlm.nih.gov/pubmed/34431759 http://dx.doi.org/10.17305/bjbms.2021.6419 |
| _version_ | 1784680699766243328 |
|---|---|
| author | Yang, Dong-Hua Chen, Zhe-Sheng |
| author_facet | Yang, Dong-Hua Chen, Zhe-Sheng |
| author_sort | Yang, Dong-Hua |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8977089 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89770892022-04-14 Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature Yang, Dong-Hua Chen, Zhe-Sheng Bosn J Basic Med Sci Commentary Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022-04 2021-08-24 /pmc/articles/PMC8977089/ /pubmed/34431759 http://dx.doi.org/10.17305/bjbms.2021.6419 Text en Copyright: © The Author(s) (2022) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
| spellingShingle | Commentary Yang, Dong-Hua Chen, Zhe-Sheng Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| title | Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| title_full | Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| title_fullStr | Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| title_full_unstemmed | Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| title_short | Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| title_sort | selection of optimal therapeutic modality for early-stage extranodal natural killer/t-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977089/ https://www.ncbi.nlm.nih.gov/pubmed/34431759 http://dx.doi.org/10.17305/bjbms.2021.6419 |
| work_keys_str_mv | AT yangdonghua selectionofoptimaltherapeuticmodalityforearlystageextranodalnaturalkillertcelllymphomapatientsundertheguidanceofsinglenucleotidepolymorphismsignature AT chenzhesheng selectionofoptimaltherapeuticmodalityforearlystageextranodalnaturalkillertcelllymphomapatientsundertheguidanceofsinglenucleotidepolymorphismsignature |